129799-11-7

Basic information

• Product Name: 4-Cbz-piperazine-2-carboxylate methyl ester
• Synonyms: PIPERAZINE-1,3-DICARBOXYLIC ACID 1-BENZYL ESTER 3-METHYL ESTER;N-4-CBZ-PIPERAZINE-2-CARBOXYLATE METHYL ESTER;METHYL-4-CBZ PIPERAZINE-2-CARBOXYLATE;MethylN-4-Cbz-piperazine-2-carboxylate;4-N-CBZ-PIPERAZINE-2-CARBOXYLIC ACID METHYL ESTER;N-4-CBZ-piperazine-2-carboxyiate methyl ester;Methyl 4-(benzyloxycarbonyl)piperazine-2-carboxylate;4-Cbz-piperazine-2-carboxylate methyl ester
• CAS NO: 129799-11-7
• Molecular Formula: C₁₄H₁₈N₂O₄
• Molecular Weight: 278.3
• Product Categories: API intermediates
• Mol File: 129799-11-7.mol

Chemical Properties

• Boiling Point: 406.5 °C at 760 mmHg
• Flash Point: 199.7 °C
• Appearance: /
• Density: 1.212 g/cm³
• Vapor Pressure: 1.88E-09mmHg at 25°C
• Refractive Index: 1.569
• Storage Temp.: 2-8°C(protect from light)
• PKA: 6.43±0.40(Predicted)
• CAS DataBase Reference: 4-Cbz-piperazine-2-carboxylate methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Cbz-piperazine-2-carboxylate methyl ester(129799-11-7)
• EPA Substance Registry System: 4-Cbz-piperazine-2-carboxylate methyl ester(129799-11-7)

Safety Data

• Hazardous Substances Data: 129799-11-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Cbz-piperazine-2-carboxylate methyl ester serves as a crucial intermediate in the synthesis of antipsychotic and antidepressant drugs. Its presence in the molecular structure of these medications aids in their therapeutic effects by modulating neurotransmitter levels and receptor interactions in the brain.
Used as a Building Block in Chemical Synthesis:
Beyond its role in pharmaceuticals, 4-Cbz-piperazine-2-carboxylate methyl ester is also employed as a building block for the production of other important chemical compounds. Its versatile structure allows for the creation of a variety of chemical entities, expanding its applications across different fields within the chemical industry.
Used in Medication Production:
4-Cbz-piperazine-2-carboxylate methyl ester is a key component in the production of numerous medications. Its inclusion in the synthesis process ensures the development of effective treatments for various conditions, highlighting its significance in the pharmaceutical sector.

InChI:InChI=1/C13H16N2O4/c16-12(17)11-8-15(7-6-14-11)13(18)19-9-10-4-2-1-3-5-10/h1-5,11,14H,6-9H2,(H,16,17)

Upstream product

• 2758-98-7 2-methoxycarbonyltetrahydropyrazine 
• 501-53-1 benzyl chloroformate 
• 181955-79-3 N,N'-di-tert-butyloxycarbonylpiperazine-2-carboxylic acid 
• 171504-98-6 O₁,O₄-di-tert-butyl O₂-methyl piperazine-1,2,4-tricarboxylate 

Downstream Products

• 225517-81-7 1-benzyl 3-methyl (3S)-piperazine-1,3-dicarboxylate 
• 1394957-81-3 1-benzyl 3-methyl (3R)-4-(3-mesitylpropanoyl)piperazine-1,3-dicarboxylate 
• 405175-79-3 (R)-4-((benzyloxy)carbonyl)piperazine-2-carboxylic acid 
• 129799-12-8 methyl 4-benzyloxycarbonyl-1-(3,4,5-trimethoxybenzoyl)-piperazine-2-carboxylate 
• 129799-14-0 4-benzyl 1-(tert-butyl) 2-methyl piperazine-1,2,4-tricarboxylate 

Relevant articles and documents

Piperazine compound and application thereof in preparation of chemokine receptor CCR2 antagonist

The invention relates to a piperazine compound as shown in a formula (I) and an application of the piperazine compound in preparation of a chemokine receptor CCR2 antagonist or a medicine for treatingCCR2-mediated diseases.

Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds

The present invention relates to novel cinnamide compounds that are useful for treating inflammatory and immunune diseases, to pharmaceutical compositions containing these compounds, and to methods of inhibiting inflammation or suppressing immune response in a mammal.

Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds

The present invention relates to novel cinnamide compounds that are useful for treating inflammatory and immune diseases and cerebral vasospasm, to pharmaceutical compositions containing these compounds, and to methods of inhibiting inflammation or suppressing immune response in a mammal.

Trisubstituted piperazine compounds, their production and use

Novel trisubstituted piperazine compounds of the formula (I) and pharmaceutically acceptable salts thereof: STR1 wherein R1, R2 and R3 are lower alkyl groups; A is a phenyl group, a hydrocarbon group formed by condensation of two or three 5- to 8-membered rings, a monocyclic 5- to 8-membered heterocyclic group containing 1 to 3 hetero-atoms selected from the class consisting of nitrogen, oxygen and sulfur, a dicyclic heterocyclic group formed by condensation of a benzene ring with a 5- to 8-membered hetero-ring containing 1 to 3 hetero-atoms selected from the class consisting of nitrogen, oxygen and sulfur, a tricyclic heterocyclic group formed by condensation of (i) a 5- to 8-membered hetero-ring containing 1 to 3 hetero-atoms selected from the class consisting of nitrogen, oxygen and sulfur, and (ii) a benzene ring, and (iii) a benzene ring or a 5- to 8-membered hetero-ring containing 1 to 3 hetero-atoms selected from the class consisting of nitrogen, oxygen and sulfur, or a styryl group of the formula: Ar--CR4 =CR5 -- wherein Ar is a phenyl group, and R4 and R5 are independently hydrogen or a lower alkyl group, the phenyl group represented by A or Ar, the hydrocarbon group represented by A, the monocyclic 5- to 8-membered heterocyclic group represented by A, the dicyclic heterocyclic group represented by A and the tricyclic heterocyclic group represented by A being unsubstituted or substituted by one or more substituents selected from the class consisting of a lower alkyl group, a halo lower alkyl group, a hydroxy lower alkyl group, an acyloxy lower alkyl group, a lower alkoxy lower alkyl group, a lower alkoxy group, a halo lower alkoxy group, a lower alkoxycarbonyl lower alkoxy group, a lower alkenyloxy group, aralkyloxy group, a lower alkoxy lower alkoxy group, a lower alkoxycarbonyl group, carboxyl group, carbamoyl group, an N,N-di-lower alkylcarbamoyl group, an N-lower alkylcarbamoyl group, halo group, cyano group, nitro group, hydroxy group, acyloxy group, amino group, a lower alkylsulfonylamino group, acylamino group, a lower alkoxycarbonylamino group, acyl group, mercapto group, a lower alkylthio group, a lower alkylsulfinyl group, a lower alkylsulfonyl group and oxo group; X is methylene group, carbonyl group or thiocarbonyl group and G is a group of the formula: --CH2 --n Z--R6 wherein n is an integer of 0 to 2, Z is a chemical bond, O, S, SO, SO2, CO, COO, OCO, OCONR7, CONR7 or NR7 (wherein R7 is hydrogen, a lower alkyl group, a lower haloalkyl group, a lower alkenyl group or a lower alkoxycarbonyl group), and R6 is hydrogen, a lower alkyl group, a lower haloalkyl group or a lower alkenyl group, provided that, when n is O and Z is chemical bond, R6 is not hydrogen or a lower alkyl group are useful as a platelet activating factor antagonist.

Trisubstituted piperazine compounds, their production and use

Novel trisubstituted piperazine compounds of the formula (I): wherein A is an optionally substituted phenyl group, an optionally substituted condensed polycyclic hydrocarbon group, an optionally substituted hetero-cyclic group or a styryl group of the formula:, Ar - CR4 = CR5 - wherein Ar is an optionally substituted phenyl group, and R4 and R5 are independently hydrogen or a lower alkyl group, X is methylene group, carbonyl group or thiocarbonyl group, G is a group of the formula:, nZ-R6 wherein n is an integer of 0 to 2, Z is a chemical bond, O, S, SO, SO2, CO, COO, CONR7 or NR7 (wherein R7 is hydrogen, a lower alkyl group, a lower haloalkyl group, a lower alkenyl group or a lower alkoxycarbonyl group), and R6 is hydrogen, a lower alkyl group, a lower haloalkyl group or a lower alkenyl group, provided that, when n is 0 and Z is chemical bond, R6 is not hydrogen or a lower alkyl group, and R1, R2 and R3 are independently a lower alkyl group, and salts thereof, are useful as a platelet activating factor antagonist.